Voya Investment Management LLC Lowers Holdings in Nurix Therapeutics, Inc. $NRIX

Voya Investment Management LLC trimmed its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 64.7% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 19,423 shares of the company’s stock after selling 35,656 shares during the period. Voya Investment Management LLC’s holdings in Nurix Therapeutics were worth $231,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC grew its position in Nurix Therapeutics by 38.9% in the first quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company’s stock worth $109,000 after acquiring an additional 2,562 shares during the period. E Fund Management Co. Ltd. purchased a new position in Nurix Therapeutics in the first quarter worth approximately $122,000. GAMMA Investing LLC grew its position in Nurix Therapeutics by 202.2% in the first quarter. GAMMA Investing LLC now owns 14,018 shares of the company’s stock worth $167,000 after acquiring an additional 9,380 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in Nurix Therapeutics in the first quarter worth approximately $169,000. Finally, Hsbc Holdings PLC grew its position in Nurix Therapeutics by 32.9% in the first quarter. Hsbc Holdings PLC now owns 16,095 shares of the company’s stock worth $189,000 after acquiring an additional 3,988 shares during the period.

Insiders Place Their Bets

In related news, insider Gwenn Hansen sold 4,308 shares of Nurix Therapeutics stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $12.01, for a total value of $51,739.08. Following the completion of the transaction, the insider directly owned 69,023 shares in the company, valued at approximately $828,966.23. This trade represents a 5.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 5,402 shares of Nurix Therapeutics stock in a transaction on Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the completion of the transaction, the chief financial officer owned 35,512 shares of the company’s stock, valued at approximately $391,697.36. This trade represents a 13.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,014 shares of company stock valued at $163,014. 7.40% of the stock is currently owned by company insiders.

Nurix Therapeutics Trading Up 3.9%

NASDAQ:NRIX opened at $9.28 on Tuesday. The firm has a market cap of $709.46 million, a PE ratio of -3.56 and a beta of 2.10. The stock has a fifty day moving average price of $9.86 and a 200 day moving average price of $10.78. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.27. The firm had revenue of $44.06 million during the quarter, compared to analyst estimates of $16.26 million. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%. Equities analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on NRIX shares. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price objective (down from $32.00) on shares of Nurix Therapeutics in a research report on Thursday, July 31st. Stephens restated an “overweight” rating and set a $30.00 price target on shares of Nurix Therapeutics in a research report on Thursday, July 10th. Baird R W upgraded Nurix Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 26th. Morgan Stanley set a $16.00 price target on Nurix Therapeutics and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Finally, HC Wainwright lowered their price target on Nurix Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.07.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.